Drugs / BCMA-GPRC5D CAR-T cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06644443 | Jul 2023 → Jul 2025 overdue | plasma cell myeloma | Shenzhen University General Hospital | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05998928 | Jul 2023 → Jul 2025 overdue | plasma cell myeloma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07376720 | Feb 2026 → Oct 2028 expected | plasma cell myeloma | Donghua Zhang | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA-GPRC5D CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05998928 ↗ |
| Modality | Cell therapy | “bispecific BCMA-GPRC5D Chimeric antigen receptor (CAR) T-cells” NCT05998928 ↗ |